(Endometrial Cancer) Is Lenvatinib + Keytruda Effective?
Medical Supporter — Мэдээллийн мэдэгдэл
Энэ нийтлэл нь олон улсын эмнэлгийн мэдээллийн эмхэтгэл бөгөөд эмнэлгийн зөвлөгөө биш; таны эмчийн оношлогоо, эмчилгээний төлөвлөгөөг орлохгүй. Энд буй мэдээлэл нь Японы томоохон эмнэлгийн байгууллагуудын нээлттэй эх сурвалжаас эмхэтгэсэн бөгөөд аливаа эмчилгээний тохиромж, үр дүн өвчтөн бүрээр өөр тул мэргэшсэн эмч тус бүрчлэн үнэлэх ёстой.
- February 3, 2022
- Reading time: 1 minute
On January 19, 2022, Vicky Makker of Memorial Sloan Kettering Cancer Center published results in The New England Journal of Medicine from the Study 309–KEYNOTE-775 Phase III clinical trial evaluating lenvatinib plus the anti-PD-1 antibody Keytruda (pembrolizumab) in advanced endometrial cancer patients with prior platinum-based chemotherapy.
The Study 309–KEYNOTE-775 Phase III trial randomized previously platinum-treated advanced endometrial cancer patients (N=827) in a 1:1 ratio to the lenvatinib arm (lenvatinib 20 mg once daily + Keytruda 200 mg every 3 weeks, N=411) or the chemotherapy arm (N=416). Primary endpoints were progression-free survival (PFS) and overall survival (OS).
Of the 827 patients, 697 were pMMR and 130 were dMMR.
Progression-Free Survival (Primary Endpoint): Median PFS was 7.2 months in the lenvatinib arm versus 3.8 months in the chemotherapy arm, representing a 44% reduction in the risk of progression or death in the lenvatinib arm. Among pMMR patients, median PFS was 6.6 months versus 3.8 months, with a 40% reduction in risk.
Overall Survival (Primary Endpoint): Median OS was 18.3 months in the lenvatinib arm versus 11.4 months in the chemotherapy arm, representing a 38% reduction in the risk of death. Among pMMR patients, median OS was 17.4 months versus 12.0 months, with a 32% reduction in risk.
Safety: Grade ≥3 adverse events occurred in 88.9% of lenvatinib arm patients versus 72.7% in the chemotherapy arm.
Based on the Study 309–KEYNOTE-775 results, Vicky Makker and colleagues concluded that lenvatinib plus Keytruda demonstrated significantly improved PFS and OS compared with chemotherapy in previously platinum-treated advanced endometrial cancer patients.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2108330?query=featured_home
- Immunotherapy
- Clinical trial drugs
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Японд эмчлүүлэхээр төлөвлөж байна уу? Мэдээлэл, тусламж хэрэгтэй юу?
Бид Японд эмчлүүлэхэд шаардлагатай мэдээллийг эмхэтгэх, Японы эмнэлгийн байгууллагуудтай холбогдох, хоёр дахь саналын зөвлөгөө зохион байгуулахад тусална.Анхны зөвлөгөө үнэгүй; зөвлөх таны дараагийн алхмыг тодорхой болгоход тусална.
Figure 1
Figure 2
Figure 3
Figure 4